Docoh
Loading...

HOLX Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Company profile

Ticker
HOLX
Exchange
Website
CEO
Stephen MacMillan
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
42902449

HOLX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

28 Apr 21
24 Jun 21
28 Sep 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 20 Sep 19 Sep 18 Sep 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Hologic earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 816.4M 816.4M 816.4M 816.4M 816.4M 816.4M
Cash burn (monthly) 17.43M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 50.81M n/a n/a n/a n/a n/a
Cash remaining 765.59M n/a n/a n/a n/a n/a
Runway (months of cash) 43.9 n/a n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 May 21 Sean S. Daugherty Common Stock Sell Dispose S No No 65.021 4,001 260.15K 26,613
11 Mar 21 Sally Crawford Common Stock Grant Aquire A No No 0 1,478 0 128,325
11 Mar 21 Sally Crawford NQSO Common Stock Grant Aquire A No No 71.03 5,055 359.06K 5,055
11 Mar 21 Scott T Garrett Common Stock Grant Aquire A No No 0 1,478 0 64,009
11 Mar 21 Scott T Garrett NQSO Common Stock Grant Aquire A No No 71.03 5,055 359.06K 5,055
11 Mar 21 Ludwig Hantson Common Stock Grant Aquire A No No 0 1,478 0 6,490
11 Mar 21 Ludwig Hantson NQSO Common Stock Grant Aquire A No No 71.03 5,055 359.06K 5,055
11 Mar 21 Namal Nawana Common Stock Grant Aquire A No No 0 1,478 0 15,191
11 Mar 21 Namal Nawana NQSO Common Stock Grant Aquire A No No 71.03 5,055 359.06K 5,055

Financial report summary

?
Risks
  • Additional resources allocated to our Diagnostics business may negatively impact our other development programs or production capacities.
  • The COVID-19 pandemic and associated economic disruptions have adversely affected and could in the future continue to have a material adverse impact on the demand for many of our products.
  • The COVID-19 pandemic and associated economic disruptions could have a material adverse effect on manufacturing, distribution and supply chain.
  • Continuing worldwide political and social uncertainty, as well as existing tariffs and trade wars and social tensions, may adversely affect our business and prospects, both domestically and internationally.
  • Our international operations and foreign acquisitions expose us to additional operational challenges that we might not otherwise face.
  • Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some key raw materials, components and subassemblies for our products exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.
  • Interruptions, delays, shutdowns or damage at our manufacturing facilities could harm our business.
  • Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, the loss of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly reduce revenues in our Diagnostics segment.
  • We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these distributors.
  • Our long-term success will depend upon our ability to execute on business development activities and integrate acquired businesses.
  • We face intense competition from other companies and may not be able to compete successfully.
  • Challenges in the development of our products could materially impact our long-term success.
  • The markets for our newly developed products and newly introduced enhancements to our existing products may not develop as expected.
  • If we cannot maintain our current corporate collaborations and enter into new corporate collaborations, our product development could be delayed and our revenue could be adversely impacted.
  • Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.
  • Guidelines, recommendations and studies published by various organizations may reduce the use of our products.
  • Increased cybersecurity requirements, vulnerabilities, threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, solutions, services and data.
  • Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or other liabilities.
  • We operate in a highly regulated industry, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products or product enhancements, could adversely affect our business and prospects.
  • Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent claims.
  • We are subject to the risk of product liability claims relating to our products for which we may not have adequate insurance.
  • We are subject to environmental, health and safety laws and regulations, including related to our use and recycling of hazardous materials and the composition of our products.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • Our business is dependent on technologies we license, and if we fail to maintain these licenses or license new technologies and rights to particular nucleic acid sequences for targeted diseases in the future, we may be limited in our ability to develop new products.
  • Our business could be harmed if we are unable to protect our proprietary technology.
  • Our business could be harmed if we infringe upon the intellectual property rights of others.
  • We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.
  • A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest payments.
  • The proposed discontinuation or replacement of LIBOR would require us to amend certain agreements and may otherwise adversely affect our business.
  • Our success depends on our ability to attract, motivate and retain key personnel and plan for future executive transitions.
  • Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our business or common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.
  • Our stock price is volatile.
Management Discussion
  • All dollar amounts in tables are presented in millions.
  • We generated an increase in product revenues in both the current three and six month periods of 121.1% and 114.2%, respectively, compared to the corresponding periods in the prior year primarily due to the significant increase in revenues in the Diagnostics business principally from sales of our two COVID-19 assays, one of which was launched near the end of the second quarter of fiscal 2020 and the other in the third quarter of fiscal 2020. The increase in product revenues in the current six
  • month period compared to the corresponding prior year period was partially offset by no revenues from the Medical Aesthetics business in the current fiscal year as we disposed of this business segment on December 30, 2019, the beginning of our second quarter of fiscal 2020.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: antimicrobial, argument, bacterial, Belgium, broader, CLIA, conference, CTGC, Defense, Diagenode, DOD, expertise, explicitly, Finland, Finnish, flat, French, gastrointestinal, lab, labor, laboratory, largely, Mobidiag, ninety, older, Oral, Oy, percent, polymerase, reaction, resistance, resurgence, RSNA, SA, satisfaction, stakeholder, Task, transplant, waiver
Removed: accelerating, approved, ATEC, earlier, Eviva, realize, recording, settling